Multinational pharmaceutical companies are masters of adaptation and transformation. They adjust their pipelines and introduce new drugs through various mergers and acquisitions and technology export agreements to meet the rapidly changing trends in the healthcare industry.

This involves a great deal of foresight. The companies need to assess the marketability of a new drug from the earliest stages of development, which is extremely costly and time-consuming.

Bristol Myers Squibb is one representative company that has been actively adapting and seeking transformation. The company, which was once considered to have no item after its hepatitis B drug 'Baraclude Tab.' and theimmuno-oncology